RMEI Educational Outcomes

View Details

Answering the Call to Action: How Nurses Have Become Progressively More Involved in Immunotherapy IME (2018 to Present)

In 2018 the Oncology Nursing Society (ONS) held an immunotherapy summit to identify and prioritize the needs of oncology nurses as they relate to patients receiving immunotherapy for cancer. In the analysis of learner data from our oncology programs we observed changes in the representation of nurses in programs focused on immunotherapy. Nurses have heeded the call to action as evidenced by their steady rise in participation since 2018. This study discusses identified areas of ongoing need for nurses in immuno-oncology.
Presentation Year: 2024
Presented at: Oncology Nursing Society (ONS)
View Details

Intravitreal Anti-VEGF & Bispecific Therapies for DME & nAMD

In late 2022, the ocular implant, insertion tool assembly, (including the drug vial & initial fill needle) for ranibizumab PDS were voluntarily recalled due to septum dislodgement and paused implantations including ongoing global clinical trials; this did not include the refill vial and needle.
Presentation Year: 2023
View Details

Cervical Cancer: What You Need to Know About Screening, Symptoms, and Treatments

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients. An estimated 13,960 women are diagnosed with invasive cervical cancer every year.
Presentation Year: 2023
View Details

Optimizing treatment in BCC and CSCC: 3 years of oncology CME

Poster presented at 19th EADO Congress, April 20-22nd, 2023.
Presentation Year: 2023
Presented at: European Association of Dermato Oncology (EADO)
View Details

Targeting BCMA: A New Path in Relapsed/Refractory Multiple Myeloma

In triple- and quad-refractory myeloma, median survival was only about 9 months, and less than 6 months in penta-refractory disease.
Presentation Year: 2023
View Details

Navigating Immunotherapy in Advanced NSCLC: What Every Oncologist Should Know

The advent of immunotherapy has significantly extended survival and revolutionized care in advanced non-small cell lung cancer (NSCLC).
Presentation Year: 2023
View Details

Is Immunotherapy Right for Your Patient with Nonmelanoma Skin Cancer?

The primary goal of treatment in nonmelanoma skin cancer (NMSC) is tumor elimination with maximal preservation of function and cosmesis.
Presentation Year: 2023
View Details

Seeing Nonmelanoma Skin Cancers Through A New Lens: The Role and Place of Immunotherapy

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.
Presentation Year: 2022
View Details

Relapsed or Refractory Chronic-Phase: CHRONIC MYELOID LEUKEMIA (CML)

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.
Presentation Year: 2021
View Details

Iterative Data-Driven Education for Evolving Strategies of Care in cSCC

The incidence of cutaneous squamous cell carcinoma (cSCC) is growing in the United States and epidemiologic data are likely to have underestimated the burden of the disease. New therapies are emerging for the management of advanced/unresectable cSCC that have the potential to alter outcomes. Clinicians need to be made aware of these new options and how they can be integrated into clinical practice. Dermatologists and Mohs surgeons will need to identify patients who are not surgical candidates and engage a multidisciplinary team to discuss systemic options, such as immunotherapy and optimal management approaches. To address the challenges facing clinicians in the appropriate alignment of treatment to patient, a 3-activity curriculum was developed. This curriculum was hosted online for one year, and findings from this education will be used to develop future content.
Presentation Year: 2020
Presented at: European Association of Dermato Oncology (EADO)